An Incisive, In-depth Analysis on the Diabetic Macular Edema Market
This study offers a comprehensive, 360 degree analysis on the Diabetic Macular Edema market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Diabetic Macular Edema market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.
Future Market Insights forecasts the global diabetic macular edema market to grow from nearly US$ 3,710 Mn in 2017 to over US$ 4,100 Mn by 2027 end. This represents a CAGR of 1.1% over the forecast period of 2017– 2027. North America is projected to be the largest market in terms of value and accounted for the highest revenue share of 51.5% in 2016.
Growing adoption of recently approved Intravitreal implants in North America
Before the launch of Lucentis for DME treatment in 2012, the use of intravitreally injected medications was less common in North America and laser photocoagulation was the primary treatment. However, Avastin and Macugen were being used off-label for diabetic macular edema treatment since 2004. Launch of three new products in 2014 viz. Eylea, Ozurdex and Iluvien, has led to the increased adoption of Intravitreal medications in North America. For instance, according to estimates of the University of Washington, before 2004, 5.75% of DME patients used Intravitreal injections, which increased to 20% by 2013. In 2016, over 70% of DME patients were utilising Intravitreal injections and implants. This sudden increase in the adoption of Intravitreal therapies can be attributed to the launch of low dose high efficacy corticosteroid implants for Intravitreal use. Uptake of Intravitreal implants by new patients as well as by patients previously treated with Intravitreal injections but who do not show any improvement, is expected to push the market for diabetic macular edema in the region.
Growing economic burden of diabetes and related disorders
Diabetic Macular Edema (DME) is a leading cause of blindness among the working age population in most developed countries. DME is one of the major complications of diabetes and DME patients utilise significantly higher healthcare resources than non-DME diabetic patients. As per a survey conducted by the University of Washington, the total yearly median cost for DME patients was reported to be US$ 14,678 and that for non-DME diabetic patients was US$ 6,801 in 2011. Moreover, DME patients have to visit their physicians for at least 30 days per year in contrast to an average of 14 visits per year in the case of non-DME diabetic patients. The growing incidences of diabetes across the globe further increase the burden of DME. According to the International Diabetic Federation (IDF), 382 Mn people worldwide have diabetes and the number is expected to grow to 592 Mn by 2035.
Gaps in making DME a health priority hampering market growth in North America
Although control of diabetes is made a health priority in developed countries such as the U.S., much attention is not given to DME management and diabetes related caregivers tend to focus on the treatment of other diabetic complications. The major reason for this is the lack of effective treatment for DME. Even though anti-VEGF and corticosteroid therapies have changed the treatment paradigm, there exists a gap in patients’ clinical information among clinicians. Furthermore, there exists an error in industry sponsored and independently run clinical trials. For instance, there are approximately 72 independent clinical trials going on for DME treatment, but most of them lack long-term results regarding safety and efficacy on new and combination therapies for diabetic macular edema. These factors are hampering revenue growth of the diabetic macular edema market in North America.
Global Diabetic Macular Edema Market Attractiveness Analysis, By Region
Western Europe is expected to be the most lucrative market for diabetic macular edema, with market attractiveness index of 2.7. Major players in the diabetic macular edema market, including Bayer AG and Novartis AG, are focussing on improving the sale of Eylea and Lucentis, respectively, in Europe. Companies are trying to exploit the full market potential and get maximum returns on R&D till patents for their drugs are alive. North America dominated the diabetic macular edema market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America is expected to be the second most lucrative among all regions, with an attractiveness index of 2.5. APEJ represents the third largest market with a market attractiveness index of 0.4. MEA is expected to remain the least attractive regional market for diabetic macular edema in revenue terms, with an attractiveness index of 0.1 over the forecast period.
Our robust and tested research methodology is behind the thoroughly scrutinised global diabetic macular edema market report
Our proven research methodology has helped us create another insightful and comprehensive report titled ‘Diabetic Macular Edema Market: Global Industry Analysis 2012 – 2016 and Forecast 2017 – 2027’. In order to infer the market size, historical data, primary responses and public domain data has been thoroughly analysed. Revenue of companies in the global diabetic macular edema market has been benchmarked to ascertain the market size for the base year. Macroeconomic indicators such as GDP and industry growth have been considered to forecast the market size over the assessment period. The historical growth trend of end-use industries, market participants’ performance, as well as the present macro-economic outlook has been taken into consideration for estimating the overall market trend forecast. This data is then validated using the triangulation method and is extensively scrutinised using advanced tools to garner quantitative and qualitative insights into the global diabetic macular edema market.
A detailed segmentation of the global diabetic macular edema market aids in the understanding of this niche market.
By Therapy Type
By Product Form
By Distribution Channel
Acetonide, Bevacizumab and
This report is divided into four parts. In the introduction, the pertinent market numbers of the global diabetic macular edema market are given along with the CAGR for the forecast period of 2017-2027. The introduction also contains an executive summary of this detailed report through which the report audience can have a cursory glance at this vast market. Also in the introduction, detailed definitions and information on diabetic macular edema are given. In addition, the macroeconomic factors influencing the global diabetic macular edema market are also given in the introduction. Diabetic macular edema market opportunity analysis is given subsequently. In addition, the economic burden of diabetic retinopathy is also stated. The global diabetic macular edema market pipeline analysis is also highlighted here.
In the next section, the regional diabetic macular edema market analysis and forecast is given. The regions are selected as per the market taxonomy. An important sub-section of the report is the market dynamics of the global diabetic macular edema market. The market dynamics section lists the drivers, restraints and trends that are applicable in the global diabetic macular edema market and discusses in detail the factors encouraging the growth of this market as well as the factors hampering the growth of this market. The various trends governing the global diabetic macular edema market – both long term and short term – are also discussed in this part of the report.
The third section of the report contains the competitive landscape of the global diabetic macular edema market. This part constitutes information on the leading companies in the global diabetic macular edema market. The competition landscape gives a dashboard view of the key companies operating in the global diabetic macular edema market along with their important information and broad strategy adopted to stay as leaders in the global diabetic macular edema market. Each of the leading companies is also profiled individually and important information about the company such as company details, company description, product portfolio along with key developments concerning the company and strategic analysis is presented. The last main section of the report contains the global diabetic macular edema market analysis and forecast by therapy type, product form, distribution channel and by region. This section presents important market metrics such as the BPS analysis, year-on-year growth rates, absolute dollar opportunity and market attractiveness analysis of the global diabetic macular edema market.
Why should you buy this report?
If you are aiming to enter the diabetic macular edema market, this report is a comprehensive guide that will provide crystal clear insights about this vast and lucrative market. All the major treatment types of diabetic macular edema are covered in this report and information is also given on the important regions of the world where this market is likely to boom in the near future, so that you can plan your strategies to enter this market accordingly. Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, then this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.